Circulating Tumor Cells Dynamics in Pancreatic Adenocarcinoma Correlate with Disease Status: Data from a Prospective Trial
Georgios Gemenetzis*, Vincent P. Groot*, Jun Yu*, Ding Ding*, Jonathan A. Teinor*, Ammar A. Javed*, Laura D. Wood*, Richard A. Burkhart*, John L. Cameron, Martin A. Makary*, Matthew J. Weiss*, Jin He*, Christopher L. Wolfgang
Johns Hopkins University School of Medicine, Baltimore, MD
Objectives: Previous retrospective studies demonstrate that circulating tumor cell (CTCs) subtypes in patients with pancreatic adenocarcinoma (PDAC) correlate with disease-specific survival. Herein, we report results of a prospective observational trial on CTC dynamics to assess their clinical significance.
Methods: The CLUSTER trial is a prospective longitudinal study on PDAC CTC dynamics (NCT02974764). Multiple peripheral blood samples are collected from 160 consecutively enrolled patients with PDAC diagnosis. CTCs are isolated and characterized by immunofluorescence.
Results: Two major CTC subtypes were identified in all patients: epithelial CTCs (eCTCs) and mesenchymal CTCs (mCTCs). Patients who received neoadjuvant chemotherapy have significantly lower total CTCs (tCTCs) and mCTCs, compared to untreated patients eligible for upfront resection (p<0.001). In multivariable logistic regression analysis, preoperative numbers of tCTCs and mCTCs were the only predictors of early recurrence and disease-associated mortality, within 12 months from surgery (p=0.03, Table 1). Surgical resection of the primary tumor results in significant reduction, but not disappearance, of CTC burden across all cell subtypes (p<0.001). Longitudinal monitoring of CTCs postoperatively shows an increase in CTC numbers within a median time of two months, prior to radiological evidence of disease recurrence.
Conclusions: We report novel findings regarding CTCs from a large prospective trial in patients undergoing PDAC resection. CTC dynamics reflect progression of disease, providing important information on clinical outcomes, not available by current tumor markers and imaging.
|logOR||95% CI||p value|
|Age, years||-0.11||-0.26 - 0.04||0.15|
|Sex, male||0.93||-1.68 - 3.55||0.46|
|Smoking Hx, present||-0.25||-1.49 - 0.97||0.66|
|BMI, kg/m2||-0.02||-0.27 - 0.23||0.86|
|Tumor site, R pancreas||-0.07||-2.28 - 2.13||0.94|
|CA 19-9, >67.8 U/mL||-0.18||-2.27 - 1.91||0.86|
|Tumor size, >3cm||1.78||-1.09 - 4.65||0.21|
|Preoperative tCTCs, >16/mL of blood||3.08||0.42 - 5.74||0.03|
|Preoperative mCTCs, >3/mL of blood||2.26||-0.17 - 4.7||0.06|
Back to 2018 Program